In December, SCYNEXIS Inc. reported progress on ibrexafungerp’s intravenous (IV) formulation and provided an update on the therapy’s ongoing Phase 3 studies in the hospital setting. SCYNEXIS has completed preclinical testing of its liposomal IV formulation of ibrexafungerp, and is moving the program into human trials in South Africa.